002644.SHE Lanzhou Foci Pharmaceutical Co Ltd
- Market cap
- CNY 3.91B
- P/E
- 63.8x
- P/B
- 2.01x
- ROE
- 3.6%
- Dividend yield
- 0.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002644.SHE undervalued?
Graham number002644.SHE trades 138.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lanzhou Foci Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Lanzhou Foci Pharmaceutical Co Ltd yet.
Lanzhou Foci Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional Chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; pre-packaged food; processing and selling of Chinese herbal medicine pieces; technology dev…
Full company profileLanzhou Foci Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lanzhou Foci Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 363M | 501M | 545M | 629M | 668M | 818M | 1.04B | 1.16B | 980M | 916M | 867M |
| Gross Profit | 108M | 148M | 176M | 173M | 164M | 221M | 304M | 359M | 299M | 312M | 280M |
| Operating Income | 64.7M | 85.2M | 87.7M | 83.0M | 130M | 112M | 143M | 83.3M | 70.4M | 126M | 97.7M |
| EBITDA | 89.1M | 110M | 123M | 138M | 177M | 160M | 182M | 135M | 120M | 121M | 81.4M |
| Net Income | 60.9M | 74.1M | 74.3M | 74.9M | 108M | 93.3M | 109M | 67.2M | 60.1M | 49.2M | 67.6M |
| EPS | 0.12 | 0.15 | 0.15 | 0.15 | 0.21 | 0.18 | 0.21 | 0.13 | 0.12 | 0.10 | 0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 2.04B | 2.35B | 2.52B | 2.40B | 2.39B | 2.35B | 2.59B | 2.53B | 2.47B | 2.55B | 2.62B |
| Total Liabilities | 746M | 991M | 1.08B | 894M | 800M | 725M | 853M | 760M | 655M | 692M | 729M |
| Shareholders' Equity | 1.29B | 1.36B | 1.44B | 1.50B | 1.58B | 1.61B | 1.72B | 1.75B | 1.79B | 1.83B | 1.87B |
| Cash & Short-term Investments | 419M | 70.2M | 466M | 435M | 452M | 375M | 398M | 406M | 398M | 524M | 654M |
| Total Debt | 108M | 109M | 17.3M | 14.5M | 34.0M | 15.5M | 14.4M | 11.3M | 12.8M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 56.9M | 66.4M | 36.7M | 47.8M | 62.9M | 11.9M | 72.4M | 65.7M | 39.0M | 184M | - |
| Capital Expenditure | 267M | 443M | 261M | 93.2M | 123M | 32.8M | 41.5M | 22.5M | 13.3M | 18.5M | 38.0M |
| Free Cash Flow | -210M | -376M | -224M | -45.3M | -59.7M | -21.0M | 30.9M | 43.2M | 25.7M | 165M | 219M |
| Ratios | |||||||||||
| ROE | 4.7% | 5.5% | 5.2% | 5.0% | 6.8% | 5.8% | 6.3% | 3.8% | 3.4% | 2.7% | 3.6% |
| ROA | 3.0% | 3.2% | 2.9% | 3.1% | 4.5% | 4.0% | 4.2% | 2.7% | 2.4% | 1.9% | 2.6% |
| Net Profit Margin | 16.8% | 14.8% | 13.6% | 11.9% | 16.2% | 11.4% | 10.4% | 5.8% | 6.1% | 5.4% | 7.8% |
| Debt to Equity | 0.08x | 0.08x | 0.01x | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lanzhou Foci Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.18%
- Forward dividend
- 0.08 CNY
- Payout ratio
- 14.3%
- Ex-dividend date
- Oct 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 7.02M | 0.01 | 14.3% |
| 2024 | CNY 16.0M | 0.03 | 26.6% |
| 2023 | CNY 27.9M | 0.05 | 41.6% |
| 2022 | CNY 5.11M | 0.01 | 4.7% |
| 2021 | CNY 61.3M | 0.12 | 65.7% |
| 2020 | CNY 30.6M | 0.06 | 28.4% |
| 2019 | CNY 6.64M | 0.01 | 8.9% |
| 2018 | CNY 6.64M | 0.01 | 8.9% |
| 2017 | CNY 6.13M | 0.01 | 8.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on Aug 14, 2015.
Who owns Lanzhou Foci Pharmaceutical Co Ltd
- Insiders 66.88%
- Institutions 1.09%
- Public & others 32.03%
- Shares outstanding 511M
- Free float 189M
Lanzhou Foci Pharmaceutical Co Ltd company profile
- Company name
- Lanzhou Foci Pharmaceutical Co Ltd
- Ticker
- 002644.SHE
- ISIN
- CNE1000019W4
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 22, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,332
- Fiscal year end
- December
- Address
- No. 2289 Huashan Road, Lanzhou, China, 730000
- Phone
- 86 93 1836 2889
- Website
- fczy.com
About Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional Chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; pre-packaged food; processing and selling of Chinese herbal medicine pieces; technology development, and professional and technical services; inspection and testing services; and production and sales of medical devices. The company exports its products. LanZhou Foci Pharmaceutical Co.,Ltd. was founded in 1929 and is based in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. operates as a subsidiary of Lanzhou Foci pharmaceutical industry development Group co., ltd.
Lanzhou Foci Pharmaceutical Co Ltd management
7- Mr. Shuangxi QianGM & Director · born 1985
- Ms. Jinfeng YueChief Financial Officer · born 1977
- Mr. Guo Lin ChaiDeputy General Manager · born 1967
- Mr. Xiao Yun FengDeputy General Manager · born 1969
- Mr. Junhui WangSecretary of the Board · born 1984
- Mr. Yingming ZhangDeputy General Manager · born 1973
- Ling WangAccounting Supervisor